Research programme: platinum therapeutics - Onc BioAlternative Names: BIO 116; BIO 158
Latest Information Update: 11 Jan 2008
At a glance
- Originator Onc Bio
- Class Platinum complexes
- Mechanism of Action Alkylating agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Oct 2005 Preclinical trials in Cancer in USA (unspecified route)